Loading…

AdaptHealth Corp.AHCOCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services
Momentum leader 82
Mkt cap
$1.01B
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$18.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.1 pp
WACC 7.6%
Hurdle
-8 pp
Req g minus delivered
Official | Implied
B+ / BB-
agencies · bond market
Next earnings
104 days
2 Mar 2027
Close · USD$7.37
1D-2.1%
1W-5.5%
1M+20.8%
3M+36.7%
6M-29.7%
YTD-26.0%
1Y-21.0%
ATR %4.7%
Beta0.24
52w lowhigh45.1% off high

What AdaptHealth does

Employees: 10,900

AdaptHealth at a glance

Size AdaptHealth (AHCO) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.01B, the 2230th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.37 on 18 Nov 2026.

Performance Over six months the shares fell 29.7%, against +4.2% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 3.2% over the last twelve months (peer median +6.8%); the operating margin is 3.2% (peer median 9.2%).

Valuation It trades at 0.9× enterprise value to sales against a peer median of 1.8× (5th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.1 points below its cost of capital (7.6% WACC).

Credit AdaptHealth has 1 bond outstanding ($500M), rated B+ by the agencies and trading like BB- at a weighted spread of 204 bp.

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 106AHCO 70
Six months, rebased to 100: AdaptHealth against the median of its 20 peers (local-currency closes).

AdaptHealth financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.15B$3.24B$3.26B$3.20B$2.97B
Revenue growth—0%+2%+8%—
Gross profit$468M$569M$636M$422M$353M
EBITDA$586M$636M$704M$661M$620M
Net income-$404M-$70.8M$82.7M-$679M$69.3M
Free cash flow$81.9M$219M$236M$143M-$17.6M
Capital expenditure$497M$382M$306M$337M$391M
Total debt$2.05B$1.90B$2.13B$2.29B$2.33B

Quarterly statements and history in the cockpit →

AdaptHealth competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%688315REG4694GDRXTHYROCARENUTXTTALOMETROPOLISOPKPNTGDIA1959401951LMRI1833USPH4544NEPHROPLUSAHCO6-month return →1-month return →
Up and to the right = strong over both horizons. AdaptHealth is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%2×4×6×688315REG4694GDRXTHYROCARENUTXTTALOMETROPOLISOPKPNTGDIA195940CLARI1951LMRI1833GMRSNEPHROPLUSAHCORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AdaptHealth is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%688315REG4694THYROCARENUTX1833GMRSAHCOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. AdaptHealth is the large dot.

AdaptHealth competitors and peer comparison

How AdaptHealth compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AdaptHealth against its 20 peers (data as of 18 Nov 2026)
MeasureAHCOPeer medianRank in peer set
1-month return+20.8%+2.0%2nd highest of 21
6-month return-29.7%+4.2%2nd lowest of 21
Distance from 52-week high-45.1%-23.8%2nd lowest of 21
Revenue growth (TTM)-3.2%+6.8%5th lowest of 21
Operating margin3.2%9.2%4th lowest of 21
EV / Sales0.9×1.8×5th cheapest of 21
Growth the price implies (Req g, 7 yrs)16.8%8.5%7th most demanding of 19
Growth delivered (Del g)+25.2%+10.7%3rd highest of 19
Hurdle (Req g minus delivered)-8.3 pp+0.8 pp7th least demanding of 19
ROIC minus cost of capital-5.1 pp-0.3 pp5th lowest of 20
EV / EBITDA5.1×10.7×3rd cheapest of 18
Net debt / EBITDA3.4×1.6×7th most indebted of 19
Bond spread204 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
AdaptHealth AHCOUnited States$1.01B-30%-3%3%0.9×16.8%+25.2%
Novogene 688315.SSChina$1.01B+13%+6%7%2.2×13.9%+8.2%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%0.9×13.3%+14.4%
BML 4694.TJapan$932M+12%+4%7%0.7×-9.0%+1.6%
GoodRx GDRXUnited States$1.15B+33%-2%12%1.8×6.3%+7.7%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%8.5×28.5%+10.9%
Nutex Health NUTXUnited States$1.19B+42%-19%39%1.8×-18.0%+253.5%
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%1.2×-5.1%+5.3%
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%6.5×32.4%+10.5%
OPKO Health OPKUnited States$1.25B+37%-22%-29%2.8×n/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%1.5×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%2.5×7.3%+18.9%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%1.3×-4.7%+12.2%
Clariane CLARI.PAFrance$1.32B-20%+1%6%1.6×6.8%+6.5%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%2.8×17.8%+12.4%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%2.1×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%0.4×3.5%-5.1%
GMR Solutions GMRSUnited States$714M-8%-4%14%0.9×-19.6%-4.0%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%2.6×18.8%+13.0%
H.U.Group 4544.TJapan$1.44B+24%+1%3%1.0×9.7%+2.1%
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%5.6×36.6%+31.6%

AdaptHealth bonds and credit

AdaptHealth has 1 bond outstanding with $500M face value. The agencies rate it B+; its bonds trade like BB-. Weighted yield 6.65%, a spread of 204 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Which companies are AdaptHealth's closest peers?
The cockpit's peer set: Novogene (688315.SS), Regis Healthcare (REG.AX), BML (4694.T), GoodRx (GDRX), Thyrocare Technologies (THYROCARE.NS), Nutex Health (NUTX), Terveystalo Oy (TTALO.HE), Metropolis Healthcare (METROPOLIS.NS).
Is AdaptHealth expensive compared with its peers?
On ev / sales it trades at 0.9× against a peer median of 1.8×, 5th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has AdaptHealth stock performed?
Over six months to 18 Nov 2026 the shares returned -29.7% against +4.2% for the median peer; over one year -21.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.